Glyxambi approval recommended by CHMP for adults with type 2 diabetes in the EU
Glyxambi is a single tablet that combines Jardiance and Trajenta and has been shown to improve blood sugar control in adults with type 2 diabetes.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Glyxambi (empagliflozin/linagliptin) for use in adults with type 2 diabetes (T2D). Glyxambi, from the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance, is a single tablet combining Jardiance (empagliflozin), a sodium glucose co-transporter-2 (SGLT2) inhibitor, and Trajenta (linagliptin), a dipeptidyl peptidase-4 (DPP-4) inhibitor.
This recommendation is based on data from three Phase III clinical trials evaluating the efficacy and safety of Glyxambi in patients with T2D. The CHMP positive opinion recommends Glyxambi, fixed dose combination of Jardiance and Trajenta, for use in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Glyxambi do not provide adequate glycaemic control, or when a patient is already being treated with the free combination of Jardiance and Trajenta.
“Half of people with type 2 diabetes do not achieve recommended blood sugar targets, so new treatment options are still needed,” said Professor Hans-Juergen Woerle, Global Vice President Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim. “We are excited about the positive opinion for Glyxambi from the CHMP. We believe that this treatment for type 2 diabetes will provide physicians and patients in Europe with another valuable option to improve blood sugar control.”
Boehringer Ingelheim and Lilly expect to receive final marketing authorisation from the European Commission in the coming months.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...